Floatz Rating
B61/100
Confidence
Indicative
Sponsor
Jian Chen
Modality
Small molecule
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
62High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT03181308CT.gov Study of Carotuximab (TRC105) Plus Nivolumab in Patients With Metastatic NSCLC | — | Completed | — | — | — |
NCT01005797CT.gov Study of Panobinostat in Combination With Sorafenib in Kidney, Soft Tissue or Lung Cancers | — | Completed | — | — | — |
NCT00954278CT.gov Intra-patient Dose Escalation Study of Sorafenib in Advanced Non-small Cell Lung Cancer | — | Completed | — | — | — |
NCT00933777CT.gov SORAVE - Sorafenib and Everolimus in Solid Tumors | — | Completed | — | — | — |
NCT00863746CT.gov A 3rd/4th Line Placebo-controlled Trial of Sorafenib in Patients With Predominantly Non Squamous Non-Small Cell Lung Cancer (NSCLC). | — | Completed | — | — | — |
NCT00922584CT.gov Sorafenib Treatment in Non-Small Cell Lung Cancer After Failure of Epidermal Growth Factor Receptor-tyrosine Kinase Inhibitor | — | Completed | — | — | — |
NCT00870532CT.gov Study of Combination of Metronomic Oral Vinorelbine and Sorafenib in Patients With Advanced Non-small Cell Lung Cancer | — | Completed | — | — | — |
NCT00635791CT.gov Phase I Study of Vorinostat and Sorafenib in Advanced Cancer | — | Completed | — | — | — |
NCT00609804CT.gov Sorafenib and Erlotinib or Sorafenib Alone in Advanced Non-Small Cell Lung Cancer Progressing on Erlotinib | — | Completed | — | — | — |
NCT00600015CT.gov Sorafenib/Erlotinib Versus Erlotinib Alone in Previously Treated Advanced Non-Small-Cell Lung Cancer (NSCLC) | — | Completed | — | — | — |
Show 13 more trialsShow fewer
NCT00801801CT.gov Study of Low Dose Chemotherapy Plus Sorafenib as Initial Therapy for Patients With Advanced Non-Squamous Cell NSCLC | — | Terminated | — | — | — |
NCT00722969CT.gov Erlotinib and Sorafenib in Chemonaive Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer | — | Unknown | — | — | — |
NCT00647426CT.gov Phase II Study of Sorafenib + Carboplatin and Docetaxel in First Line Treatment of Stage IIIB/IV NSCLC | — | Completed | — | — | — |
NCT00558636CT.gov A Trial Comparing Safety and Efficacy of Carboplatin and Paclitaxel Plus or Minus Sorafenib (BAY43-9006) in Chemonaive Patients With Stage IIIB-IV Non-Small Cell Lung Cancer (NSCLC) | — | Terminated | — | — | — |
NCT00532025CT.gov Sorafenib in Resected Non-small Cell Lung Carcinoma | — | Terminated | — | — | — |
NCT00417248CT.gov Cisplatin/Etoposide/Radiotherapy Followed by Consolidation Sorafenib for Inoperable Stage III Non-Small Cell Lung Cancer | — | Terminated | — | — | — |
NCT00473486CT.gov Study in Patients With Advanced Non-Small Cell Lung Cancer Treated With Pemetrexed and Carboplatin Plus or Minus Sorafenib | — | Terminated | — | — | — |
NCT00449033CT.gov A Phase III Randomized, Double-blind, Placebo Controlled Trial Comparing the Efficacy of Gemcitabine, Cisplatin and Sorafenib to Gemcitabine, Cisplatin and Placebo in First-Line Treatment of Patients With Stage IIIb With Effusion and Stage IV Non-Small Cell Lung Cancer (NSCLC) | — | Completed | — | — | — |
NCT01069328CT.gov Dose Escalating Study With BAY43-9006 With Carboplatin, Paclitaxel and Bevacizumab in Untreated Stage IIIb Non-small Cell Lung Cancer (NSCLC) | — | Completed | — | — | — |
NCT00300885CT.gov A Randomized Controlled Trial Comparing Safety and Efficacy of Carboplatin and Paclitaxel Plus or Minus Sorafenib (BAY 43-9006) in Chemonaive Patients With Stage IIIB-IV Non-Small Cell Lung Cancer (NSCLC) | — | Terminated | — | — | — |
NCT00098254CT.gov BAY 43-9006 (Sorafenib) to Treat Relapsed Non-Small Cell Lung Cancer | — | Completed | — | — | — |
NCT00098540CT.gov Sorafenib in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer | — | Completed | — | — | — |
NCT00101413CT.gov BAY43-9006 - Phase II Study in Non-Small Cell Lung Carcinoma (NSCLC) | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
59High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Non-Small Cell Lung Carcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Sorafenib (this asset) | Jian Chen | P3 | B · 61 |
| Necitumumab | Jonsson Comprehensive Cancer Center | P3 | BBB |
| Glumetinib | Shanghai JMT-Bio Inc. | P3 | BBB |
| Veliparib | AbbVie | P3 | BBB |
| d-0316 | Betta Pharmaceuticals Co., Ltd. | P2/3 | BBB |
| Icotinib | The First Affiliated Hospital of Guangzhou Medical University | P4 | BBB |
| Zoledronate | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | P4 | BBB |
| Onartuzumab | Hoffmann-La Roche | P3 | BBB |
| Avitinib | Hangzhou ACEA Pharmaceutical Research Co., Ltd. | P3 | BBB |
+42 more in the Non-Small Cell Lung Carcinoma cohort
Other indications for Sorafenib
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Renal Cell Carcinoma | — | P4 | BBB · 79 |
| Portal Vein Thrombosis | — | P4 | BBB · 74 |
| Adult Hepatocellular Carcinoma | — | P3 | BBB · 73 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Sorafenib in Non-Small Cell Lung Carcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/sorafenib-non-small-cell-lung-carcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →